ArticleImmunologic research2026
Human endogenous retroviruses antibody signatures in severe asthma phenotypes.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Human endogenous retroviruses (HERVs) represent approximately 8% of the human genome and have been increasingly implicated in the pathophysiology of immune-related disorders. In this study, we investigated the humoral response against specific antigenic peptides derived from HERV-H, HERV-K, and HERV-W in the plasma of patients across different asthma phenotypes, including non-severe and severe cases, compared to healthy controls (HCs). Our results show that antibody levels against HERV-W were significantly low in the asthmatic population, showing a progressive downregulation that was more pronounced in severe cases. Conversely, a distinct and robust upregulation was uniquely observed for HERV-H in severe asthma cases, reaching a 100% positivity rate. Furthermore, HERV-K antibody levels were significantly lower in the non-severe asthmatic subtype compared to HCs. Interestingly, Spearman analysis revealed significant positive correlations among all tested HERV peptides within the Asthmatic cohort, a co-regulatory trend that became substantially reinforced within the Severe Asthma subgroup. These findings highlight a specific immune dysregulation pattern where a synchronized HERV expression tightly correlates with disease severity and phenotypical classification. The HERV epitopes identified in this exploratory study appear to be key targets of the humoral response in asthmatic patients, suggesting that circulating antibody levels against these retroviral elements could serve as potential tools for exploratory disease stratification and refractory phenotype characterization.
Indexed as
Identifiers
42848098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.